Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms
Jorge Berlanga‐Acosta(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Viviana Falcón‐Cama(Centro de Ingeniería Genética y Biotecnología), Juan Valiente-Mustelier, Danay Cibrián(Instituto de Salud Carlos III), Linlin Wang(Chinese Academy of Sciences), Ariana García‐Ojalvo(Centro de Ingeniería Genética y Biotecnología), Baohong Jiang(Chinese Academy of Sciences), José Suárez-Alba(Centro de Ingeniería Genética y Biotecnología)
Cited by 13
Related Papers
CD69: from activation marker to metabolic gatekeeper
|European Journal of Immunology|2017|935
Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation
|Nature Communications|2016|597
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153